https://www.bioworld.com/rss en-us Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732472 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732472-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732473 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732473-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Biopharma financings across all categories totaled $59.76 billion on 567 deals in the first half (H1) of 2026, more than double H1 2025’s $29.53 billion across 501 transactions. http://www.bioworld.com/articles/732277 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732277-h1-2026-biopharma-financings-double-from-last-year-approach-pandemic-highs Blocks with upward arrows Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732271 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732271-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732393 Wed, 01 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732393-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies. http://www.bioworld.com/articles/732154 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732154-chinas-micot-targets-hk12b-ipo-to-advance-metabolic-portfolio IPO, coins, upward arrow J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment. http://www.bioworld.com/articles/732153 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732153-j-pharma-drives-first-cancer-lat1-to-phase-iii-study-with-fda-nod Illustration of cancer in the bile ducts J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment. http://www.bioworld.com/articles/731921 Thu, 18 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731921-j-pharma-drives-first-cancer-lat1-to-phase-iii-study-with-fda-nod Illustration of cancer in the bile ducts Cardiovascular-focused Kardigan Inc. is the latest biopharma firm to take advantage of the wide open IPO window, pricing an upsized offering of 25 million shares at $16 per share, the high end of its proposed range, to rake in gross proceeds of about $400 million. http://www.bioworld.com/articles/731920 Thu, 18 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731920-biopharma-ipos-stay-strong-as-kardigan-prices-upsized-400m-offering Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies. http://www.bioworld.com/articles/731909 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731909-chinas-micot-targets-hk12b-ipo-to-advance-metabolic-portfolio IPO, coins, upward arrow Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed it. The oncology-focused firm priced its upsized IPO of 3.5 million shares at $20 apiece for gross proceeds of $670 million, an amount that could rise to $770 million should underwriters exercise their full 5-million-share overallotment option. http://www.bioworld.com/articles/731719 Wed, 10 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731719-parabilis-takes-top-spot-pricing-largest-biopharma-ipo-at-670m Virtual IPO word with stock graph and arrow Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch. http://www.bioworld.com/articles/731832 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731832-hemab-soars-89-on-debut-as-biopharma-ipos-stay-strong-in-may Gray and green glass dollar symbols with arrow pointing up Total med-tech financing through the first five months of 2026 reached $11.01 billion, falling between 2024’s $12.76 billion and 2023’s $8.95 billion over the same period, and trailing 2025’s $14.83 billion. http://www.bioworld.com/articles/731709 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731709-med-tech-ipo-window-holds-with-151b-raised-through-may-in-2026 Business, data, dollars illustration Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch. http://www.bioworld.com/articles/731635 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731635-hemab-soars-89-on-debut-as-biopharma-ipos-stay-strong-in-may Gray and green glass dollar symbols with arrow pointing up Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody. http://www.bioworld.com/articles/731646 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731646-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody. http://www.bioworld.com/articles/731445 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731445-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com In a move aimed at incentivizing companies to go and stay public, the U.S. SEC proposed two rulemakings May 19 as a foundation to the agency’s Make IPOs Great Again agenda. http://www.bioworld.com/articles/731369 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731369-sec-looks-to-reforms-to-make-ipos-great-again Biopharma financing activity is continuing its rebound in early 2026 compared to the past several years. Total funding reached $38.66 billion in the first four months of 2026, more than doubling 2025’s $15.85 billion in the same period and also exceeding 2022 and 2023. While still below the peak years of 2021 and 2024, when financings topped $50 billion in the period, the 2026 total shows a strong recovery. http://www.bioworld.com/articles/731229 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731229-kaileras-record-ipo-headlines-strong-april-for-biopharma-financings Financial markets rebound illustration Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and 2022’s $10.62 billion. While below the peak years of 2019-2021, when financings were above $15 billion in the time period, total value is still above the levels seen in 2023-2024. April saw $1.51 billion raised, compared to $2.44 billion in March, $4.55 billion in February and $1.52 billion in January. http://www.bioworld.com/articles/731228 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731228-follow-ons-hit-7-year-high-lead-med-techs-10b-start-to-2026 Dollar sign thermometer Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day. http://www.bioworld.com/articles/731227 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731227-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m ​Star Sports Medicine HKEX IPO ceremony Star Sports Medicine's IPO ceremony on May 5. Credit: HKEX; x.com – @HKEXGroup Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the largest biotech raise on the Hong Kong Stock Exchange this year to date. Hangzhou, China-based Metis is an AI-based nanoparticle drug formulation and delivery-focused company. Synthetic lethality-based cancer drugmaker Impact Therapeutics Inc., of Shanghai, plans to debut on the same day with a US$117 million IPO. http://www.bioworld.com/articles/731048 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731048-metis-techbio-impact-tx-cleared-for-hong-kong-ipos Businessman and IPO virtual screen Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and 2022’s $10.62 billion. While below the peak years of 2019-2021, when financings were above $15 billion in the time period, total value is still above the levels seen in 2023-2024. April saw $1.51 billion raised, compared to $2.44 billion in March, $4.55 billion in February and $1.52 billion in January. http://www.bioworld.com/articles/730985 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730985-follow-ons-hit-7-year-high-lead-med-techs-10b-start-to-2026 Dollar sign thermometer Mobia Medical Inc. began trading on Nasdaq under the ticker MOBI on May 8. The company priced its IPO at the midpoint of its proposed $14 to $16 range, selling 10 million shares at $15 each and raising approximately $150 million. The stock closed at $11.75 its first day of trading, down 21.7%. http://www.bioworld.com/articles/730982 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730982-mobia-debuts-on-nasdaq-to-bring-stroke-therapy-to-more-patients Mobia Medical Vivistim system Vivistim Paired VNS system. Credit: Mobia Medical Inc. Raising $279 million in an IPO and another $25 million in a concurrent private placement, Odyssey Therapeutics Inc. is advancing its lead phase II asset, OD-001, in ulcerative colitis, with plans to bring its SLC15A4 program into the clinic for lupus. http://www.bioworld.com/articles/730980 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730980-odysseys-ipo-placement-brings-304m-to-lead-drugs-in-ibd-lupus IPO, coins, financial chart Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day. http://www.bioworld.com/articles/730868 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m ​Star Sports Medicine HKEX IPO ceremony Star Sports Medicine's IPO ceremony on May 5. Credit: HKEX; x.com – @HKEXGroup Biopharma financing activity is continuing its rebound in early 2026 compared to the past several years. Total funding reached $38.66 billion in the first four months of 2026, more than doubling 2025’s $15.85 billion in the same period and also exceeding 2022 and 2023. While still below the peak years of 2021 and 2024, when financings topped $50 billion in the period, the 2026 total shows a strong recovery. http://www.bioworld.com/articles/730866 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730866-kaileras-record-ipo-headlines-strong-april-for-biopharma-financings Financial markets rebound illustration Privately-funded biotechs in Switzerland raised a record CHF1.15 billion (US$1.47 billion) in 2025, an increase of 38% over 2024, and 45% of the total capital raised by the sector. This was a significant advance on previous years, when private companies typically attracted about 30% of overall investment. http://www.bioworld.com/articles/730865 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730865-swiss-biotech-reports-record-private-investment-employment-in-2025 Swiss currency Continuing biopharma’s IPO resurgence in 2026, Hemab Therapeutics Holdings Inc. priced an upsized offering of 16.75 million shares at $18 per share, the high end of its proposed price range, for gross proceeds of $301.5 million. Another $45 million could come if underwriters exercise their full overallotment. http://www.bioworld.com/articles/730765 Fri, 01 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730765-hemab-prices-301m-in-latest-upsized-biopharma-ipo IPO and digital hologram with business icons Seaport Therapeutics Inc. joined Nasdaq May 1, raising gross proceeds of $254.9 million, as its parent, Boston-based Puretech Health plc moved to exit the market, opting for a sole listing on the London Stock Exchange (LSE) in order to reduce its cost base and cut bureaucracy. http://www.bioworld.com/articles/730764 Fri, 01 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730764-seaport-joins-nasdaq-as-parent-puretech-delists-sticks-with-lse Stock exchange board The memory of Merck & Co. Inc.’s $10 billion takeover last year of inhaled respiratory drug specialist Verona Pharma plc may not have been far from the minds of Wall Street speculators as Avalyn Pharma Inc. priced its IPO, selling about 16.6 million shares at the high end of the targeted range, or $18 each, to reap about $300 million. The stock (NASDAQ:AVLN) came out of the gate strong on the first day of trading and closed April 30 at $29.49, up $11.49, or 64%. http://www.bioworld.com/articles/730746 Thu, 30 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730746-mists-of-avalyn-thicken-with-300m-ipo-for-inhaled-drugs Going public ticker